After a peptide is synthesized, purified, and packaged, one quality check has nothing to do with the peptide itself. It looks for bacterial endotoxins: fragments shed by certain bacteria during their normal life cycle and death. They are invisible, heat-stable, and capable of triggering severe physiological responses at very low concentrations. Knowing what they are and how labs test for them is part of judging any injectable compound's safety profile.
What Bacterial Endotoxins Are
Endotoxins are lipopolysaccharides (LPS), complex molecules found in the outer membrane of gram-negative bacteria such as E. coli and Salmonella. When these bacteria die or replicate, fragments of their cell wall (LPS among them) are released into the surrounding environment. Endotoxins are not living organisms, so they cannot be "killed." Standard sterilization such as autoclaving (typically 121 °C moist heat) destroys bacteria but leaves endotoxin fragments intact and biologically active. Removing or inactivating endotoxin instead requires dedicated depyrogenation, such as dry heat at 250 °C for 30 minutes.
Once in the bloodstream, endotoxins interact with the immune system's toll-like receptor 4 (TLR4) pathway, a mechanism well-described in immunology literature. Research reports that even small amounts can trigger a cascade of inflammatory signaling, leading to fever, chills, and in severe cases a systemic inflammatory response sometimes called endotoxemia or, at its most extreme, septic shock. Endotoxin exposure through intact membranes, as with oral or topical products, matters far less. For injectables the risk is different in kind.
Why Injectables Require Endotoxin Testing
Pharmaceutical regulators including the FDA, EMA, and USP require endotoxin limits for injectable drugs as a standard part of release testing. The USP chapter <85> (Bacterial Endotoxins Test) and its international equivalents define the accepted methods and limits. The per-product endotoxin limit is calculated as K/M. K is the threshold pyrogenic dose, 5 EU/kg of body weight for most parenteral routes and a stricter 0.2 EU/kg for intrathecal administration. M is the maximum recommended human dose per kilogram in a single hour. The specific limit therefore varies by product, dose, and route, so always defer to official pharmacopoeial references for precise figures.
Research-use peptides are compounds synthesized for laboratory or investigational purposes and not approved for human use or consumption. They are not formally subject to the same regulatory release testing as licensed pharmaceuticals. But third-party labs that specialize in peptide quality assessment increasingly offer endotoxin testing as a reported data point, which lets researchers assess contamination in the same framework regulators use.
How Labs Measure and Report Endotoxins
The long-standing testing method is the Limulus Amebocyte Lysate (LAL) test, which uses a clotting agent derived from horseshoe crab blood (Limulus polyphemus). LAL reagent is extremely sensitive to LPS. In the presence of endotoxin it triggers a detectable clotting or color-change reaction, with detection limits commonly in the 0.01–0.1 EU/mL range. A newer alternative, the recombinant Factor C (rFC) assay, reaches comparable sensitivity without horseshoe crab-derived material.
The regulatory status of animal-free reagents moved forward in this period. The USP Microbiology Expert Committee approved a dedicated new chapter, USP <86> (Bacterial Endotoxins Test Using Recombinant Reagents), on July 26, 2024, published it for early adoption in November 2024, and made it official in May 2025. Per USP, <86> covers both recombinant Factor C (rFC) and recombinant cascade reagents and complements <85> rather than replacing it. Labs using LAL can continue to do so. The European Pharmacopoeia likewise recognizes rFC as an accepted method.
Results are reported in EU/mL (endotoxin units per milliliter of solution). One USP Endotoxin Unit (EU) equals one International Unit (IU), defined against a reference endotoxin preparation. The USP maintains its Reference Standard Endotoxin (RSE), calibrated against the WHO International Standard for Endotoxin. Labs such as Janoshik and others in the third-party peptide-testing space typically report a numeric EU/mL value alongside the method used and the assay's detection limit. A result below that threshold is reported as "less than X EU/mL" rather than zero, which reflects the limit of measurement.
| Term | What it means |
|---|---|
| EU/mL | Endotoxin units per milliliter of solution tested |
| LAL test | Limulus Amebocyte Lysate — long-standing method using horseshoe crab lysate |
| rFC assay | Recombinant Factor C — animal-free alternative to LAL |
| Detection limit | Lowest concentration the assay can reliably detect; results below are reported as "<X EU/mL" |
| USP <85> | US Pharmacopeia chapter defining the bacterial endotoxin test methods and acceptance criteria |
| USP <86> | US Pharmacopeia chapter (official May 2025) covering endotoxin testing with recombinant reagents such as rFC |
When you review a third-party certificate of analysis (COA), the endotoxin result should specify the method, the reported value or detection limit, and ideally the sample preparation method, since dilution factors and matrix effects can influence results. A COA that lists only a pass/fail, with no numeric value or method, is harder to verify than one with full detail.
Sources
- USP Bacterial Endotoxins Test (USP <85>) — usp.org
- USP: Expert Committee approves endotoxin testing using non-animal-derived reagents (USP <86>) — usp.org
- FDA Guidance on Endotoxin Testing — fda.gov
- EMA Guidelines on Endotoxins for Parenteral Products — ema.europa.eu
- PubMed: LPS and TLR4 signaling literature — pubmed.ncbi.nlm.nih.gov
- Janoshik Analytical Testing (third-party COA provider) — janoshik.com
- Finnrick Peptide Lab Test Aggregator — finnrick.com